Aktie A2DP21 GB SCIENCES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen GB Sciences, Inc. Other OTC

Aktien

A2DP21

US3615441090

GBLX

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
GB Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
GB Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
GB Sciences, Inc. Auditor Raises 'Going Concern' Doubt
Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of Lethbridge
GB Sciences, Inc. announced a financing transaction
GB SCIENCES INC : Change in Directors or Principal Officers (form 8-K)
GB Sciences, Inc. Announces Executive Changes
GB SCIENCES INC : Submission of Matters to a Vote of Security Holders (form 8-K)
GB SCIENCES INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
GB SCIENCES INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients
TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DP21 Aktie
  4. A2DP21 Aktie
  5. Nachrichten GB Sciences, Inc.
  6. Andere Sprachen